A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)

NCT04147234 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

INDUSTRY

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: BI 1387446 50 μg
DRUG: BI 754091
DRUG: BI 1387446 100 μg
DRUG: BI 1387446 200 μg
DRUG: BI 1387446 400 μg

Sponsor

Boehringer Ingelheim